Novel pandemic influenza A (H1N1) and community-associated methicillin-resistantStaphylococcus aureuspneumonia

作者：Doo Ryeon Chung, Kyungmin Huh · 发表于：Expert Review of Anti-infective Therapy · 年份：2015 · DOI：10.1586/14787210.2015.999668 · 被引用次数：30 · 研究领域：Pneumonia and Respiratory Infections、Antimicrobial Resistance in Staphylococcus、Influenza Virus Research Studies

Postinfluenza bacterial pneumonia is a leading cause of influenza-associated death, and Staphylococcus aureus and Streptococcus pneumoniae have been important pathogens that have caused pneumonia since the influenza pandemic in 1919. Emergence of novel influenza A (H1N1) pdm09 and the concomitant global spread of community-associated methicillin-resistant S. aureus (CA-MRSA) have led to increasing prevalence of CA-MRSA pneumonia following influenza infection. Such an epidemiologic change poses a therapeutic challenge due to a high risk of inappropriate empiric antimicrobial therapy and poor clinical outcomes. Early diagnosis and initiation of appropriate antimicrobial therapy for post-influenza bacterial pneumonia have become even more important in the era of CA-MRSA. Therefore, novel molecular diagnostic techniques should be applied to more readily diagnose MRSA pneumonia.